Squarepoint
TSHA icon

Squarepoint’s Taysha Gene Therapies TSHA Stock Holding History

Squarepoint’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.88M Buy
569,269
+158,987
+39% +$941K ﹤0.01% 1789
2026
Q1 		$1.83M Sell
410,282
-61,295
-13% -$285K ﹤0.01% 2239
2025
Q4 		$2.59M Buy
471,577
+273,225
+138% +$1.33M ﹤0.01% 1875
2025
Q3 		$649K Buy
198,352
+98,126
+98% +$278K ﹤0.01% 3018
2025
Q2 		$232K Buy
+100,226
New +$218K ﹤0.01% 3884
2025
Q1 		– Sell
-211,842
Closed -$366K – 5428
2024
Q4 		$366K Buy
211,842
+108,719
+105% +$226K ﹤0.01% 4004
2024
Q3 		$207K Buy
103,123
+22,868
+28% +$50.2K ﹤0.01% 3669
2024
Q2 		$180K Sell
80,255
-133,691
-62% -$389K ﹤0.01% 3687
2024
Q1 		$614K Buy
213,946
+150,469
+237% +$314K ﹤0.01% 2907
2023
Q4 		$112K Buy
63,477
+34,909
+122% +$69.6K ﹤0.01% 3733
2023
Q3 		$90.3K Sell
28,568
-52,066
-65% -$97.2K ﹤0.01% 3575
2023
Q2 		$53.3K Buy
+80,634
New +$58.4K ﹤0.01% 3436
2022
Q1 		– Sell
-29,210
Closed -$340K – 3538
2021
Q4 		$340K Buy
+29,210
New +$441K ﹤0.01% 2380

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Squarepoint's TSHA Position: Q2 2026 in Review

Squarepoint increased its Taysha Gene Therapies (TSHA) stake by 39% in Q2 2026, buying an estimated $941K and bringing the position to 569,269 shares worth $3.88M. The position accounts for ﹤0.01% of the portfolio, ranked #1789.

Squarepoint first reported a position in TSHA in Q4 2021 and has held it in 13 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Squarepoint held 569,269 shares of Taysha Gene Therapies worth $3.88M as of Q2 2026.
  • Squarepoint bought 158,987 Taysha Gene Therapies shares in Q2 2026, an estimated $941K.
  • Taysha Gene Therapies made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #1789 holding.
  • Squarepoint first reported a position in Taysha Gene Therapies in Q4 2021 and has held it in 13 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.